Obesity and overweight are estimated to have caused a staggering $30.1 billion reduction in Florida economy in 2022, equivalent to 2.2% of the state's gross domestic product, according to a...
Obesity and overweight are estimated to have caused a staggering $89.5 billion reduction in California economy in 2022, equivalent to 2.5% of the state's gross domestic product, according to a...
Obesity and overweight are estimated to have caused a staggering $19.9 billion reduction in Pennsylvania’s economy in 2022, equivalent to 2.2% of the state's gross domestic product, according to...
Obesity and overweight are estimated to have caused a staggering $7.2 billion reduction in Alabama’s economy in 2022, equivalent to 2.6% of the state's gross domestic product, according to a...
Obesity and overweight are estimated to have caused a staggering $17.6 billion reduction in Illinois’ economy in 2022, equivalent to 1.7% of the state's gross domestic product, according to a...
Obesity and overweight are estimated to have caused a staggering $425.5 billion in economic costs to U.S. businesses and employees in 2023, according to a report released by GlobalData Plc, a...
Obesity and overweight are estimated to have caused a staggering $5.7 billion reduction in Iowa’s economy in 2022, equivalent to 2.5% of the state's gross domestic product, according to a report...
Obesity and overweight are estimated to have caused a staggering $37.3 billion reduction in New York’s economy in 2022, equivalent to 1.8% of the state's gross domestic product, according to a...
Obesity and overweight are estimated to have caused a staggering $9.3 billion reduction in Indiana's economy in 2022, equivalent to 2% of the state's gross domestic product, according to a report...
Presenting companies include: Teva Pharmaceuticals Industries, BioForum, Pharma Focus Israel and DATATRAK International CLEVELAND, Feb. 9 /PRNewswire-FirstCall/ -- DATATRAK International, Inc...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales